News | January 17, 2025
AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Subscribe To Our Newsletter & Stay Updated
